Genmab — September 2019

[bibob]

In the meantime we wanted to snap-poll MS-treating neurologists to gauge opinion towards the different dosing regimens which are use administer Ocrevus and Ofatumumab and which have been citer as a potential means of competive differentation

[StockBull]

Ser umidlbart ud til der er folk som vil supplere i 1355-1360 så måske et rebound senere på dagen op mod de 1400

[polle1]

Var det ikke meningen/forudsigelsen, at det netop skulle være je

[polle1]

her i september vi skulle peake ift alle de store kurstriggere som har været omtalt længe her ?

[Peter_Panik]

Føj for en åbning da!

[Peter_Panik]

Det var så 100 kr. ned siden toppen i sidste uge!

[bibob]

Det har vi da prøvet et utal af gange. Alt pharma får tæsk idag.

[StockBull]

Polle. Sikkert stadig sektor rotation der er igang. Både Genmab, Novo og Ørsted er banket tilbage til deres støtteområder. Har selv suppleret ligt Novo og Ørsted i håb om støtten holder. Genmab er jeg tungt lastet

[polle1]

@stockbull, fandme ikke nemt

[JohnW]

Mon ikke det bare er en generel korrektion i markedet?

[StockBull]

Høj volatilitet p.g.a sektor rotation, Trump, B.J m.m

[Bella1]

og heldagsregn, - ikke at forglemme

[StockBull]

derudover ser det ud til danske aktier for flere bank end dax og us

[E_L]

German immunotherapy biotech BioNTech files for a $100 million US IPO https://www.nasdaq.com/article/german-immunotherapy-biotech-biontech-files-for-a-100-million-us-ipo-cm1209253

[E_L]

FORM F-1 https://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330df1.htm

[E_L]

We are developing, in collaboration with Genmab, novel next-generation bispecific antibodies that are designed for conditional activation of immunostimulatory checkpoint molecules. Our first bispecific candidates are GEN1046 (BNT311), which targets PD-L1 in conjunction with 4-1BB, and GEN1042 (BNT312), which targets CD40 in conjunction with 4-1BB

[E_L]

While 4-1BB is a known immune checkpoint target that is expressed on T cells and natural killer, or NK, cells, prior attempts to target 4-1BB with monoclonal antibodies have been severely limited by liver toxicities. Our 4-1BB targeting product candidates are designed to avoid toxicities by conditionally activating a 4-1BB receptor only together with the binding of either PD-L1 or CD40. We have initiated Phase 1/2a trials of GEN1046 (BNT311) and GEN1042 (BNT312) in solid tumors.

[E_L]

interesting on the liver toxicity which Jan also mentioned before

[E_L]

and also GEN1042 has initiated according to this

[E_L]

it was taken out of clinicaltrials a while ago, as you may remember. (I understand on a recent investor conference in Holland, Jan said that it is the next product candidate planned for the clinic)